ClinicalTrials.gg
RecruitingNCT06109701Updated Feb 2, 2024

Efficacy of Air-polishing on Pain Perception and Compliance Rate

An interventional study of Debridement with ultrasonic device and scaling with plastic curettes and Debridement with erythritol based air-polishing powde in Peri-Implantitis and Peri-implant Mucositis, sponsored by Universitat Internacional de Catalunya. Recruiting at 1 site in Spain. Open to participants aged 21 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-02.

Sponsored by Universitat Internacional de Catalunya · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Jun 2023, registered Sep 2023).
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya — 6 open to participants now, 6 under way, none of them phase 3. Peri-Implantitis · Universitat Internacional de Catalunya.

Started
2023
with 1 other
No phase
7 of 15
4 open now
Registered
12th of 15
by date

Among the 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya, this one is one of 2 that started in 2023, is one of 7 with no phase, and was the 12th registered.

Peri-Implantitis

324 studies on the registry are indexed under Peri-Implantitis; 89 are open to participants now.

Browse Peri-Implantitis studies →

Open to participants now

6 of the 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 50 Peri-Implantitis studies recruiting now, 28 (56%) set no upper age limit and 9 (18%) stop at 75 or younger; 7 take children under 18; 26 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya, or all of them as a file.
02

Study summary

Implants have become a popular and widely used treatment option for treating partial and total edentulism. As the number of implants placed increases, so does the incidence of peri-implant mucositis and peri-implantitis. Placing patients under SPT/maintenance care has been shown to prevent and treat such conditions. Despite SPT's importance in prevention and infection control, adherence to scheduled SPT visits have been unsatisfactory. Understanding the reasons for non-compliance can help both the clinician and research community to address them by improving patients experience to those visits thereby increasing compliance.

Read the detailed description

Objectives:

  1. General objective Evaluate the patient reported outcomes to a different implant instrumentation method during SPT visits, as well as its effect in compliance rates and clinical outcomes.
  2. Specific objective

    1. To evaluate pain/discomfort during SPT around dental implants and teeth.
    2. To evaluate pain/discomfort during SPT around healthy and diseased dental implants.
    3. To evaluate patient reported outcomes and clinical variables by decontamination during SPT with erythritol based air polishing powder (Air Flow Master, Air-Flow Plus, EMS, Nyon, Switzerland), at the first SPT, at 1 and 2 years.
    4. To evaluate the effect of erythritol based air polishing powder (Air Flow Master, Air-Flow Plus, EMS, Nyon, Switzerland) during SPT on the compliance rates after 1 and 2 years of follow-up.
    5. Hypothesis:

a) General Hypothesis The proposed protocols, focused on the prevention of peri-implantitis, will result in an increase adherence to SPT by better understanding the specific factors related to non-compliance, specifically by improving the experience of patients to SPT visits.

b) Specific Hypothesis

  1. SPT with conventional ultrasonic device will result in more pain/discomfort around dental implants than in teeth.
  2. SPT by means of an erythritol based air-polishing powder (Air Flow Master, Air-Flow Plus, EMS, Nyon, Switzerland) will result in better patient reported outcomes and same clinical outcomes, at the first SPT and after 2 years.
  3. SPT by means of an erythritol based air-polishing powder (Air Flow Master, Air-Flow Plus, EMS, Nyon, Switzerland) will result in the increase of the compliance rates after 2 year of follow-up.
  1. Material y Methods: Study Design The present research project is designed as a randomized controlled clinical trial with a 2-year follow-up. The reporting of this clinical trial will follow the Consolidated Standards of Reporting (CONSORT) guidelines.

Subject Selection The study will be performed after the approval of the Ethics Committee of the Universitat Internacional de Catalunya (UIC) and will be conducted according to the principles outlined in the Declaration of Helsinki and Ethical Conduct for Research with Human Beings.

A list of patients who have been enrolled in SPT at the Department of Periodontology of UIC and met the inclusion criteria will be used - patients will be called once every 2 days (with a maximum of 3 attempts) for a SPT visit by the same investigator (E.R).

  • SPT visit One calibrated investigator will consecutively call patients for SPT visits and will be responsible of enrolling the patients (E.R).

The study variables will be recorded in a case report form (CRF) specially designed for the study. Each study patient will be assigned a numerical code comprising a 3-digit patient code (assigned correlatively as they are included in the study). Only the study investigator will be able to identify the patient by their code.

Screening examination The clinician will review with the patient the Information and Medication History Forms and record the anthropometric, socio-demographic and clinical information. Candidates will undergo an oral pathology examination and a full-mouth manual probing using a periodontal probe PCP-UNC 15 (HuFriedy, Rockwell St, Chicago, IL) to determine their periodontal and peri-implant status. Presence or absence of plaque will be recorded after staining with an erythrosine disclosing dye (Plac-Control®, Dentaid SL, Cerdanyola, Spain). Finally, periapical radiographs (Dürr Dental AG, Bietigheim-Bissingen, Germany) of all implants will be taken using a paralleling cone technique and a film-holder (7mA- 60kV/20ms).

The same calibrated examiner (E.R) will record clinical variables of mPI, BOP, PPD, MR and clinical attachment level (CAL).

Randomization and study groups Once oral hygiene instructions were provided, patients will be randomly assigned to the Test or Control groups. Allocation of patients will be decided following randomization tables with permuted blocks of four while the information will be concealed by using opaque envelopes, which will be labelled with the patient study number and only be revealed after oral hygiene instructions are provided.

Questionnaires A blinded calibrated examiner (C.V) will give each patient the following questionnaires.

Pain Perception Pain experienced during the SPT visit will be recorded using the Visual Analog Scale (VAS). A horizontal 10 cm VAS (graded from zero, representing no pain, to 10, representing the worst pain possible) will be used by the patients immediately after finishing the supragingival debridement around teeth, and then, after performing supragingival debridement around the dental implants.

Modified Dental Anxiety Scale (MDAS) Another questionnaire (MDAS) will be used to measure patient anxiety towards SPT visit in both groups. The MDAS consists of five questions answered with a 5-category Likert scale, ranging from 'not anxious' to 'extremely anxious'. The original MDAS questionnaire does not cover anxiety toward SPT visits. Therefore, a question enquiring about patients' feelings toward SPT visit will be added. Patients will complete the modified MDAS once, after finishing the SPT visit.

  • Follow-up SPT visits Patients enrolled in the study will be called for SPT every 4 months (to standardize every patient during the time of the study) and supragingival debridement will be performed accordingly to their group (control or test). All clinical and microbiological variables will be re-examined by the same blinded examiner (E.R) after the first SPT visit (4 months), at 1 year and 2 years of follow-up. Additionally, a periapical radiograph of all implants involved in the study will be taken at 1 year and 2 years of follow-up. Individual compliance will be registered as well in the CRF.

Patients will be further motivated with respect to oral hygiene habits during the entire period of the study.

Clinical examination A guidebook will be prepared to standardize procedures throughout the protocol, step by step, for all questionnaires and evidence collection. The data will be transferred to a computerized database.

The study variables will be recorded in a case report form (CRF) specially designed for the study. Each study patient will be assigned a numerical code comprising a 3-digit patient code (assigned correlatively as they are included in the study). Only the study investigator will be able to identify the patient by their code.

Determination of recurrent sites and re-treatment needs Sites will be determined as re-treatment needs if they show PD ≥ 4 mm and CAL ≥ 4 mm in more than 2 non-adjacent teeth, together with the presence ≥10% of BOP and/or SU (around teeth) and if they show PD ≥ 6mm, together with BOP and/or SU, and bone levels ≥3 mm apical of the most coronal portion of the intraosseous part of the implant (around dental implants), during SPT appointment. Individuals will be treated with non-surgical or surgical procedures, where necessary, by postgraduate students of the Periodontology Department at the CUO (UIC).

Intra-examiner reproducibility Reproducibility of clinical examinations will be conducted by the examiner (E.R), evaluating the Implant PPD and mBI in 5 patients, not involved in the study, on two separate occasions, 1 week apart. The intra-class correlation coefficient and the kappa index will be calculated. Calibration will be accepted when measurements at baseline and at one-week evaluation will be within a difference of 0.5 mm >90% of the time.

Withdrawal of consent The Patient Information Sheet will clearly state that the patient can withdraw from the study at any time without prejudice or explanation. Such withdrawal will be documented in the medical record file. Losses to follow-up are taken into account in the sample size calculations (12%).

Statistical analysis Descriptive analysis Descriptive statistical methods (percentage and numbers on total) will be used to analyze the evaluated parameter Inferential analysis Data will be calculated at patient level and implant/tooth level. VAS score will be considered as the main outcome (quantitative).

If the distribution is normal, the following tests will be used:

  • Binary categorical variables: T-Student / Fisher's exact test;
  • Categorical variables with > 2 categories: ANOVA;
  • Quantitative variables: Simple linear regression / Pearson correlation coefficient.

If it doesn't follow normality:

  • Binary categorical variables: U of Mann-Whitney;
  • Categorical variables> 2 categories: H of Kruskal-Wallis;
03

Conditions studied

  • Peri-Implantitis
  • Peri-implant Mucositis

Browse trials for

Keywords

  • Peri-implantitis
  • prevention
  • peri-implant mucositis
  • pain perception
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Partially edentulous patients, rehabilitated with at least one dental implant in the maxilla or mandible with at least 3 years of function;
  • No implant mobility;
  • Treated periodontal disease;
  • Non-smoker or light smoking status in smokers (\<10 cigarettes/day).

Exclusion criteria

Exclusion Criteria:

  • Patients with diagnosed fibromyalgia disorder or who are taking drugs that might influence the perception of pain (i.e., opioids, gabapentin) will be excluded from the study (Alcalde et al. 2017).
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
38 participants (estimated)

Study arms

  • Active comparator
    Control Group - Ultrassonic Devices

    Supra and sub-gingival debridement with an ultrasonic device (DTE-D5, Woodpecker®, Guilin, China) with a plastic tip (Hu-Friedy®, Rockwell St, Chicago, IL, USA) and scaling with plastic curettes (Hu-Friedy®, Rockwell St, Chicago, IL, USA) around dental implants and a conventional metal tip for teeth will be used.

    Procedure: Debridement with ultrasonic device and scaling with plastic curettes

  • Experimental
    Test Group - Erythritol based air-polishing powder

    Supra and sub-gingival debridement with an erythritol based air-polishing powder (Air-Flow, EMS, Nyon, CH) will be used during 5 seconds on each site (Schwarz et al., 2015).

    Procedure: Debridement with erythritol based air-polishing powde

Interventions

  • ProcedureDebridement with ultrasonic device and scaling with plastic curettes

    Supragingival and subgingival debridement

    Also known as: Supportive periodontal / peri-implant treatment

  • ProcedureDebridement with erythritol based air-polishing powde

    Supragingival and subgingival debridement

    Also known as: Supportive periodontal / peri-implant treatment

06

What researchers measure

Primary outcomes

  1. Patient Pain/Discomfort (VAS) reported after decontamination during SPT.

    0 = no pain and 10 = extreme, unbearable pain

    Time frame: immediately after the procedure

Secondary outcomes

  1. Compliance to Supportive Periodontal Treatment (SPT) reported after decontamination during SPT.

    Regular Complier = 3- to 6-month recall interval (≥2 SPT/year) Erratic Complier = 7- to 12-month recall interval (\<2 SPT/year) Non-Complier = no recall interval program (no SPT/year)

    Time frame: 24 months

  2. Changes in Full mouth plaque index (FMPI)

    Full mouth plaque index (FMPI) will be assessed dichotomously at four sites per tooth (mesial, buccal, distal and lingual). Presence or absence will be recorded after staining with an erythrosine disclosing dye (Plac-Control®, Dentaid SL, Cerdanyola, Spain). Presence of plaque will be scored if an area of clearly stained material is present along the gingival margin and if this material can be removed with the side of the probe. The percentage of surfaces with plaque out of the total number of examined tooth surfaces will be calculated

    Time frame: 24 months

  3. Changes in Full mouth plaque index (FMBI)

    Full mouth bleeding index (FMBI) will be assessed dichotomously as presence or absence of bleeding after 30 seconds of gently probing. The proportion of bleeding surfaces out of the total number of examined surfaces will be calculated (Ainamo and Bay, 1975).

    Time frame: 24 months

  4. Changes in Periodontal probing depth (PPD)

    Full mouth PPD measured at six aspects around tooth.

    Time frame: 24 months

  5. Changes in gingival recession (GR)

    Gingival Recession (GR) will be recorded at six aspects per implant: mesial buccal, buccal, disto-buccal, mesio-lingual, lingual and disto-lingual.

    Time frame: 24 months

  6. Changes in modified Plaque Index (mPI)

    mPI will be measured at six aspects around implants: Score 0 - no detection of plaque. Score 1 - plaque only recognized by running a probe across the smooth marginal surface of the implant. Score 2 - plaque can be seen by the naked eye. Score 3 - abundance of soft matter.

    Time frame: 24 months

  7. Changes in modified Bleeding Index (mBI)

    mBI will be assessed 30 seconds after 0.15 N force probing. Score 0 - no bleeding. Score 1 - isolated bleeding spots visible. Score 2 - blood forms a confluent red line on margin. Score 3 - heavy or profuse bleeding. This variable will be dichotomized in presence/absence of bleeding and will serve as the main variable.

    Time frame: 24 months

  8. Changes in suppuration on probing (SOP)

    SOP evaluated after assessing dichotomously the presence of suppuration within 30 seconds after gentle probing.

    Time frame: 24 months

  9. Changes in Implants probing depth (implant PPD)

    Implant PPD, measured from the mucosal margin to the bottom of the probable pocket, determined at six aspects per implant: mesial-buccal, buccal, disto-buccal, mesial-lingual, lingual and disto-lingual with a resin splint.

    Time frame: 24 months

  10. Changes in Mucosal Recession (MR) around dental implants

    MR at dental implants will be recorded at six aspects per implant: mesial-buccal, buccal, disto-buccal, mesial-lingual, lingual and disto-lingual.

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2024, 18 months after the start.

Of 121 non-industry interventional studies with no phase under Peri-Implantitis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 46. This study's planned 18 months is below that.

Counting every sponsor, half of 128 studies reached it within 26 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2023
First posted
Oct 31, 2023
StartActual
Jun 1, 2023
Primary completionEst.
Dec 31, 2024
CompletionEst.
Jun 1, 2025
Last update
Feb 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06109701
Responsible party
Tiago Ribeiro Amaral (PhD candidate, Universitat Internacional de Catalunya) — Principal investigator
First posted
Oct 31, 2023
Start date
Jun 1, 2023
Primary completion
Dec 31, 2024 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Feb 2, 2024

Study contacts

Tiago R Amaral, Dentist
Contact
tamaral@uic.es
+351916067069
Cristina V Vallès, Dentist
Contact
cristinavallveg@uic.es
Cristina V Vallès, Dentist
principal investigator · Universitat Internacional de Catalunya

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion